Intelligence Platform
Patents
Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12428379
Acylsulfonamide KAT6A inhibitors
granted patentUS 12428487
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide an
granted patentUS 12427155
Treatment for tau-related diseases
granted patentUS 12428376
Therapeutic compounds and compositions
granted patentUS 12428416
ERK inhibitors and uses thereof
granted patentUS 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted patentUS 12427132
Method of improving sleep
granted patentUS 12427151
Compositions and method of treating cancer
granted patentUS 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted patentUS 12427212
Nectin-4 binding miniproteins, conjugates and uses thereof
granted patentUS 12428408
Fused heterocyclic mescaline derivatives
granted patentUS 12428415
Matriptase 2 inhibitors and uses thereof
granted patentUS 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted patentUS 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of
granted patentUS 12427111
Lipid nanoparticles
granted patentUS 12427125
Method for treating SARS and treating or preventing ARDS
granted patentUS 12427137
Method for reducing methane production in animal stomach
granted patentUS 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted patentUS 12427170
Universal donor cells
granted patentUS 12427171
Krill oil composition enriched in LPC-DHA and LPC-EPA
granted patentUS 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted patentUS 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonis
granted patentUS 12428395
Heterocyclic compounds as kinase inhibitor and uses thereof
granted patentUS 12428489
Human PD-L2 antibodies and methods of use therefor
granted